Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Urologic Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Pancreatic Intraductal Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Hemorrhage 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Merkel Cell 1 Breast Neoplasms 1 Advanced Ovarian Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 62 Nivolumab 40 Ipilimumab 24 trametinib 13 dabrafenib 10 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 binimetinib 9 Cyclophosphamide 8 CTLA-4 Antigen 8 Biopsy 8 encorafenib 7 fludarabine 6 Radiosurgery 6 Cisplatin 6 relatlimab 5 cemiplimab 5 atezolizumab 5 Pemetrexed 5 Introns 5 Interleukin-2 5 tislelizumab 4 lenvatinib 4 fludarabine phosphate 4 durvalumab 4 dostarlimab 4 cobimetinib 4 avelumab 4 Radiotherapy 4 Paclitaxel 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Melanoma × Saline Solution × Clear all

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡